Sorrento Therapeutics (LTS:0L85) ROE % Adjusted to Book Value: 0.00% (As of Jun. 2023)


LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics ROE % Adjusted to Book Value?

Sorrento Therapeutics LTS:0L85 12 ROE % Adjusted to Book Value is 0.00% as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

Sorrento Therapeutics's ROE % for the quarter that ended in Jun. 2023 was 0.00%. Sorrento Therapeutics's PB Ratio for the quarter that ended in Jun. 2023 was N/A. Sorrento Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was N/A.

Sorrento Therapeutics ROE % Adjusted to Book Value Related Terms

Sorrento Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics ROE % Adjusted to Book Value Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -74.27 -25.70 -21.67 -18.58 0.00

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -73.18 -47.90 0.00 0.00 0.00

LTS:0L85 vs IMUX, OCUP, KZR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Sorrento Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sorrento Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's ROE % Adjusted to Book Value falls into.


LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics ROE % Adjusted to Book Value Calculation

Sorrento Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-1,904.94% / N/A
=N/A

Sorrento Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Sorrento Therapeutics (LTS:0L85) has a ROE % Adjusted to Book Value of 0.00% as of Jun. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sorrento Therapeutics and its competitors.
Is Sorrento Therapeutics' ROE % Adjusted to Book Value too high?
Sorrento Therapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sorrento Therapeutics' ROE % Adjusted to Book Value compare to IMUX and OCUP?
Sorrento Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sorrento Therapeutics and its competitors. Sorrento Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sorrento Therapeutics stock overvalued right now?
Sorrento Therapeutics (LTS:0L85) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current ROE % Adjusted to Book Value is 0.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price